Molecular Targeted Agents and Biologic Therapies for Non-Small Cell Lung Cancer

The document reviewed various molecular targeted agents and biologic therapies for non-small cell lung cancer (NSCLC) as of 2010, including EGFR inhibitors like Erlotinib and Gefitinib, VEGF inhibitors such as Bevacizumab and Sorafenib, monoclonal antibodies, small molecule inhibitors, and immunomodulatory agents targeting pathways like HER2, FGFR, VEGFR, IGF-1R, and mTOR. These therapies were in different phases of clinical trials, with some already FDA-approved for other cancers. Common side effects included skin toxicity, diarrhea, hypertension, fatigue, nausea, and hyperglycemia. The document emphasized the potential of these therapies in treating NSCLC and the need for further research to establish their efficacy and safety.